Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

New HIV diagnosis and baseline assessment

Essential points for quick revision.

Saved on this device
!
New HIV with possible organ-threatening opportunistic disease

Hypoxia, neurological change, meningism, visual disturbance, shock, marked wasting or severe gastrointestinal disease may be the first evidence of advanced immune failure and cannot wait for routine clinic staging.

Action: Stabilise with an ABCDE approach and involve HIV plus the organ-specific acute team. Obtain samples and imaging directed by the presentation, begin time-critical infection treatment, and select ART timing from the confirmed syndrome and its own current guideline rather than applying one interval to every opportunistic infection.

Synopsis

Confirm and explain a new HIV diagnosis, identify immediate clinical danger, and turn the first specialist encounter into a safe, individualised treatment and prevention plan.

  • Screen with a laboratory fourth-generation HIV-1/2 antigen–antibody assay, and submit every reactive result to the national confirmation pathway before calling it a definitive diagnosis.
  • Very early infection may precede antigen, antibody or rapid-test reactivity, so request HIV RNA when the exposure and illness suggest acute HIV; hypoxia, neurological change or visual loss also triggers immediate syndrome-directed specialist care.
  • Discuss the result privately and without blame, arrange same-day HIV-service linkage, and before or at ART initiation obtain CD4, viral load, genotype, blood count, renal and liver tests, hepatitis B and C, exposure-site STI tests and pregnancy assessment when relevant.

Key red flags

Breathlessness with dry cough and hypoxia in advanced HIV raises concern for Pneumocystis pneumonia and requires urgent oxygenation assessment, blood gas and chest imaging.

Headache, confusion, meningism, a focal deficit or reduced consciousness needs urgent specialist CNS investigation; safe sampling and ART sequencing depend on the syndrome found.

New floaters, reduced acuity or a field defect during severe immune suppression requires same-day HIV and ophthalmology review with dilated retinal examination.

A febrile rash illness with pharyngitis or lymphadenopathy after recent exposure may be primary HIV even when an early antigen–antibody result is negative.

Severe weight loss, prolonged diarrhoea, oesophageal symptoms, oral candidiasis or recurrent infection makes advanced immune deficiency clinically likely before the CD4 result returns.

A person receiving a reactive antenatal or donor screen needs prompt confirmation, privacy, support and specialist linkage before the preliminary result is framed as final.

Acute seroconversion presentation

Fever, diffuse rash, sore throat, lymphadenopathy, diarrhoea, myalgia, headache or aseptic meningitic symptoms after recent risk should prompt RNA testing when serology is early.

Advanced immune presentation

Dyspnoea, wasting, chronic diarrhoea, oesophageal pain, neurological features or atypical skin disease suggests major CD4 depletion and demands same-day assessment.

Immediate psychosocial risk

Self-harm thoughts, overwhelming distress, partner violence, coercion, housing insecurity or confidentiality danger need active support during diagnostic care.

Investigation priorities

01
Fourth-generation laboratory HIV-1/2 assayFirst step

Detect p24 antigen and antibody as the standard screening step for many established and early infections.

Management branches

Reactive resultVerify and communicate diagnosis

A screening laboratory or point-of-care result has returned reactive.

  1. Clarify that the result is preliminary, protect privacy and assess immediate emotional safety before giving more technical detail.
  2. Send the required confirmatory samples and check whether recent exposure, PrEP or PEP makes HIV RNA particularly important.

Key medicines

Specialist-selected rapid-start ARTPrescribe a complete approved regimen, commonly once daily and integrase inhibitor based, after baseline samples with adjustment for resistance, HBV, pregnancy, kidney function and interactions.Never assemble partial treatment; reconcile cations, rifamycins, anticonvulsants and other interacting products, and maintain the HBV-active components required by coinfection.
Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mgTake one combined tablet by mouth once daily when the HIV specialist confirms that this complete regimen fits the patient.Check resistance, HBV, kidney and pregnancy context plus rifamycins, anticonvulsants and polyvalent cations; it is not an automatic choice for every new diagnosis.
Open full textbook Answer 2 questions
Sources and review status5 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom